共 39 条
- [3] Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : 2793 - 2806
- [7] The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (05): : 1390 - 1400
- [8] Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)) [J]. ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (09) : 1629 - 1635